Madison, United States
Elephas, founded in 2020 and headquartered in the United States, is making significant strides in the intersection of AI, Biotechnology, and Health Care. The company's slogan, "Live tumor profiling for immunotherapy response prediction," highlights its core innovation: an ex-vivo platform that analyzes live patient biopsies for immunotherapy response.
The Elephas Live platform distinguishes itself by preserving the tumor's native microenvironment, allowing for real-time characterizations of immune responses. This approach provides a novel solution to the challenge of tumor heterogeneity, positioning the company as a promising player in personalized cancer treatment.
Recently, Elephas secured a substantial $55.00M Series C investment on 24 January 2024, with notable backers including Sands Capital Ventures, Moore Strategic Ventures, Northpond Ventures, and others. This funding round underscores investor confidence in Elephas's potential to revolutionize cancer care through innovative technology.
Orakl Oncology